Recent News

• 03.24.2026 - Rezolute Provides Update on its Congenital Hyperinsulinism Program Following FDA Meeting
• 03.04.2026 - Rezolute to Participate in the Citizens Life Sciences Conference
• 02.12.2026 - Rezolute Reports Second Quarter Fiscal 2026 Financial Results and Provides Business Update
• 02.04.2026 - Rezolute to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
• 01.07.2026 - Rezolute Provides Insights from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism and Shares Findings from its Expanded Access Program in Tumor Hyperinsulinism

Recent Filings

• 03.04.2026 - 4 Statement of changes in beneficial ownership of securities
• 03.04.2026 - 4 Statement of changes in beneficial ownership of securities
• 03.04.2026 - 4 Statement of changes in beneficial ownership of securities
• 02.13.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 02.12.2026 - EX-99.1 EX-99.1
• 02.12.2026 - 8-K Current report
• 02.12.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 02.11.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 01.30.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 01.08.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors